

BEST PRACTICES IN: Oral Contraception Counseling: Recommendations for Best Practices

This supplement is the third of three articles on oral contraception. The content is based on the proceedings of an experts' roundtable held on November 4, 2010, in Miami, Florida, with panelists:

- David J. Portman, MD
- Mandy Gittler, MD
- Christopher Estes, MD, and
- Versie Johnson-Mallard, PhD, MSN, MSMS.

The first installment appeared in the February 2011 issue of *OB.GYN. NEWS*®. The second installment appeared in the April 2011 issue.



Versie Johnson-Mallard, PhD, MSN, MSMS
Robert Wood Johnson Nurse Faculty Scholar
University of South Florida
Tampa, FL

bleeding, not necessarily for family-planning methods.” The conversation provides an opportunity to introduce OCs to women who are not using contraception and, among women already taking an OC, the opportunity to assess satisfaction and adherence.

Often, commented Dr Johnson-Mallard, adherence and satisfaction are intertwined. Patients will often reveal how important dates (eg, weddings), recreational and sporting activities, and vacations are planned around anticipated bleeding dates—either menstrual bleeding or withdrawal bleeding dates. In fact, in a survey of 270 women without menstrual-related diagnoses, 75.6% said that menstrual periods interfered with sexual activity, 28.8% preferred not having their menstrual period when at work, and 48.4% reported that menstrual periods interfered with exercise and sports.¹ More than half of the women (n=152) in the survey desired reducing menstrual frequency. Ascertaining such information helps inform and direct the type of counseling needed for individual women.


Key Counseling Messages

Key OC counseling messages are detailed in the Table² and should include efficacy, safety, and side effects, as well as return to fertility, noncontraceptive benefits (eg, predictability and less bleeding), and, importantly, continued use of condoms to protect against STIs.

Counseling should also include discussions of extended-regimen OCs, said Dr Johnson-Mallard. Although the US Food and Drug Administration approved an extended-regimen OC in 2003, women are often unaware of the safety associated with having only four withdrawal bleeds per year. They are also unaware that extended regimens reduce bleeding frequency and the menstrual-like withdrawal symptoms that occur with 21/7 regimens. These factors, combined with the more convenient dosing, which are appealing to many women, may improve adherence, commented Dr Johnson-Mallard.

In fact, after counseling, women frequently switch to extended regimens.³ In a retrospective analysis of 318 women taking 21/7 regimens and experiencing hormonal withdrawal symptoms, 91% chose to switch to an extended regimen after counseling (Figure 1).³ At 5-year follow-up, 46% of these women continued with an extended regimen.

Figure 1. Most Common Reasons Women Switch to an Extended-Regimen Oral Contraceptive (OC)³




Key counseling messages for extended-regimen OCs do not differ greatly from those provided for 21/7 regimens. However, there are two additional key points. First, when introducing extended-regimen OCs, clinicians should reassure women that amenorrhea is safe when using an OC and is an indication of efficacy, and that the absence of bleeding does not portend “exploding,” said Dr Johnson-Mallard. Women starting extended-regimen OCs also need to be reassured that breakthrough spotting/bleeding will diminish over time and that, in total, there is less bleeding with extended regimens than with no OC or 21/7 regimens.

Counseling and Adherence

Counseling women about OC options, efficacy, and bleeding can and does improve adherence and satisfaction, said Dr Johnson-Mallard. Counseling about extended regimens often leads to extended-regimen use, and extended regimens are associated with better adherence than are other methods.^{3,4} For example, an analysis of OC prescription refill rates among 2.7 million women found that prescription refill rates after 12 months of use were substantially higher than with other methods, including 21/7 regimens. The 12-month refill rate for branded 28-day regimens was 29% versus 34.5% for drospirenone-containing pills and 31% for extended regimens (p<0.001, Figure 2).

Counseling also improves patient satisfaction and adherence by providing women with the knowledge to accept transient unscheduled bleeding, a common cause of dissatisfaction, poor adherence,

Figure 2. Timely Refill Rates Higher With Extended Regimens⁴



and discontinuation.^{5,6} Dr Johnson-Mallard explained, “There is a cycle. A woman misses a pill and has unscheduled bleeding. She stops the pill, but is now at risk for pregnancy, and so she restarts the pill. As she restarts the pill, there is again the possibility of unscheduled bleeding. This is the point: we need to talk about emergency contraception and consistent pill use. Education, education, education.”

Case Study

An 18-year-old woman, a patient for the last 4 years, presented in March seeking an OC. She was a high school senior and planning to attend college in the fall. She reported virginal status but was interested in starting an OC. The initial counseling session included the following messages:

- All OCs are highly efficacious when taken correctly.
- OC use is safer than pregnancy.
- Minor side effects may occur upon initial use.
- Consistent use is essential for efficacy.
- Condom use is essential if she becomes sexually active to prevent STIs.

She was prescribed a 21/7 OC.

In December, during the winter break, the young woman returned to the office seeking alternatives to her current OC. She was sexually active and reported that her current method of OC worked well for her and her partner. However, she was also a varsity basketball player and, because of her frequent game schedule, found the monthly withdrawal bleeds inconvenient and asked about other options.

Given the young woman's history, an extended-regimen OC was an obvious choice. She was again counseled on adherence, safety, and side effects, and the importance of consistent condom use to protect against STIs. In addition to safe-sex counseling, key messages to compliance included:

- Unscheduled bleeding may be a common side effect but should diminish over time.
- Unscheduled bleeding may be more common in the first 3 to 4 months of use.
- Adherence to a pill regimen is important.

Conclusion

Counseling, adherence, and contraceptive success are inseparable. Ongoing counseling during each office visit can help ensure that women are satisfied with their contraceptive choices, and satisfaction improves adherence. In addition to safety and efficacy data, counseling sessions should include information about options for withdrawal bleeding frequency, how different regimens may change lifestyle, and the continued need for prevention of STIs.

References

1. Ferrero S, Abbamonte LH, Giordano M, et al. What is the desired menstrual frequency of women without menstruation-related symptoms? *Contraception*. 2006;73:537-541.
2. Nelson AL. Communicating with patients about extended-cycle and continuous use of oral contraceptives. *J Womens Health (Larchmt)*. 2007;16:463-470.
3. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. *Am J Obstet Gynecol*. 2002;186:1142-1149.
4. Nelson AL, Westhoff C, Schnare SM. Real-world patterns of prescription refills for branded hormonal contraceptives: A reflection of contraceptive discontinuation. *Obstet Gynecol*. 2008;112:782-787.
5. Hickey M, Agarwal S. Unscheduled bleeding in combined oral contraceptive users: Focus on extended-cycle and continuous-use regimens. *J Fam Plann Reprod Health Care*. 2009;35:245-248.
6. Bachmann G, Korner P. Bleeding patterns associated with oral contraceptive use: A review of the literature. *Contraception*. 2007;76:182-189.

Table. Key Points for Oral Contraceptive (OC) Counseling²

Contraceptive Efficacy
<ul style="list-style-type: none"> • All OCs are highly efficacious when taken correctly • Missed doses may lead to decreased efficacy of the OC, especially with 21/7 regimens • Precautionary methods should be discussed in the event of a missed dose
Safety
<ul style="list-style-type: none"> • OCs are clearly safer than pregnancy • Risk of venous thrombosis should be discussed, and signs and symptoms should be clearly described, as should other rare health risks
Side Effects
<ul style="list-style-type: none"> • Minor side effects may occur upon initial use, including nausea, breast tenderness, and unscheduled bleeding • These side effects usually subside within the first few months of initiation
Fertility
<ul style="list-style-type: none"> • Fertility returns rapidly upon discontinuation of OC use • Patients should be told to start using another method of contraception as soon as they stop using OCs; they should not wait until their next period
Noncontraceptive Benefits
<ul style="list-style-type: none"> • Bleeding is decreased with all OCs • OCs provide greater cycle predictability if taken cyclically • All OCs are associated with a decreased risk of benign breast disease, pelvic inflammatory disease, and ovarian and endometrial cancers
Other
<ul style="list-style-type: none"> • OCs do not protect against sexually transmitted infections

Source: Nelson²

This supplement was produced by International Medical News Group, a division of Elsevier Medical Information, LLC. Neither the editor of *OB.GYN. NEWS*®, the Editorial Advisory Board, nor the reporting staff contributed to its content. The opinions expressed in this supplement are those of the faculty and do not necessarily reflect the views of the supporter or of the Publisher.

Copyright © 2011 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher.

Elsevier Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein. The opinions expressed in this supplement do not necessarily reflect the views of the Publisher.

Editorial Support provided by Josh Paul.

Faculty Disclosure: Dr Johnson-Mallard has nothing to disclose.